Lupin Ltd - Company Profile
Powered by 
All the data and insights you need on Lupin Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Lupin Ltd Strategy Report
- Understand Lupin Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lupin Ltd (Lupin) develops and manufactures generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It has expertise in the areas of cardiovascular, asthma, diabetic management, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB, and cephalosporins. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, diabetes, tuberculosis, inflammation and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries operates manufacturing facilities in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
B/4 Laxmi Towers, , Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra, 400055
Website
www.lupin.com
Telephone
91 22 66402323
No of Employees
18,971
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LUPIN (NSE)
Revenue (2022)
$2.1B
1.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
128.1%
(2022 vs 2021)
Market Cap*
$8.7B
Net Profit Margin (2022)
XYZ
127.7%
(2022 vs 2021)
* As of and is in US$
Lupin Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anti-Tuberculosis: Tablets and Capsules | Rcinex |
| Diabetes Management: Tablets, Injections, Capsules, Insulin Cartridge and Devices | Akurit |
| Cardiac Care: Tablets, Injections, Capsules and Injectables | AKT |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In April, the company introduced the first generic version of Oracea in the US. |
| 2024 | Regulatory Approval | In March, the company received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Eslicarbazepine Acetate Tablets. |
| 2024 | Regulatory Approval | In March, the company received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Aripiprazole Tablets to market a generic equivalent of Abilify Tablets of Otsuka Pharmaceutical Company, Ltd. |
Competitor Comparison
| Key Parameters | Lupin Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Divi's Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Mumbai | Hyderabad | Mumbai | Hyderabad |
| State/Province | Maharashtra | Maharashtra | Telangana | Maharashtra | Telangana |
| No. of Employees | 18,971 | 41,000 | 24,832 | 26,615 | 16,950 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ramesh Swaminathan | Chief Financial Officer; Head of Corporate Affairs; Director | Executive Board | 2020 | 57 |
| Rakesh Bhardwaj | Chief Information Officer | Senior Management | 2024 | - |
| Shahin Fesharaki | Chief Scientific Officer | Senior Management | 2022 | - |
| Ranjana Pathak | Chief Quality Officer | Senior Management | 2024 | - |
| Mr. Christoph Funke | Chief Technical Operations Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward